TY - JOUR
AU - 
AB - ISSN: 2377-3634 Babu and Eligar. Int J Diabetes Clin Res 2021, 8:146 DOI: 10.23937/2377-3634/1410146 Volume 8 | Issue 3 International Journal of Open Access Diabetes and Clinical Research REViEw ARticlE Oral Semaglutide: A Novel Oral Preparation of GLP-1 Receptor Agonist 1 2* Priya Mohan Babu and Vinay Eligar Check for Specialty Registrar, University Hospital of Wales, Cardiff, UK updates Consultant in Diabetes and Endocrinology, University Hospital of Wales, Cardiff, UK *Corresponding author: Dr. Vinay S Eligar, Consultant in Diabetes and Endocrinology, University Hospital of Wales, Cardiff, CF14 4XW, UK Administration (FDA) for use in the management of Introduction Type 2 diabetes. The glucagon-like peptide-1 (GLP-1) is an endogenous It can be used for the treatment of adults with hormone produced by the L cells in the intestine. It is insufficiently controlled type 2 diabetes mellitus to released in response to the intake of food and intestinal improve glycaemic control as an adjunct to diet, dilatation. It stimulates the pancreatic beta-cell to exercise and secrete insulin which is dependent upon ingestion of food. GLP-1 acts to slow down gastric motility and 1. As monotherapy when metformin is suppress appetite through the GLP-1 receptors in the considered inappropriate due to intolerance 
TI - Oral Semaglutide: A Novel Oral Preparation of GLP-1 Receptor Agonist
JO - International Journal of Diabetes and Clinical Research
DO - 10.23937/2377-3634/1410146
DA - 2021-09-30
UR - https://www.deepdyve.com/lp/unpaywall/oral-semaglutide-a-novel-oral-preparation-of-glp-1-receptor-agonist-5s6ShM69x7
DP - DeepDyve
ER -